Aripiprazole Tablet
Product Images NDC 71205-480

8 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71205-480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

Aripiprazole Structure (Aripiprazole Str)
Chemical structure of Aripiprazole displayed as a series of interconnected rings and chains, including chlorine atoms and nitrogen-containing groups. The structure illustrates the molecular framework of this active pharmaceutical ingredient used in tablet form.*
FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)
A chart showing the effects of other drugs on aripiprazole pharmacokinetics, specifically fold changes in AUC and Cmax with 90% confidence intervals. It compares the influence of CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs.*
FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)
A chart showing the effects of various drugs on the pharmacokinetics of dehydro-aripiprazole. The x-axis represents the fold change relative to a reference without interacting drug, ranging from 0 to 3. The y-axis lists different inhibitors, inducers, and blockers such as ketoconazole (CYP3A4 inhibitor), quinidine (CYP2D6 inhibitor), carbamazepine (CYP3A4 inducer), famotidine (gastric acid blocker), valproate, and lorazepam, with corresponding AUC and Cmax measurements shown as data points with 90% confidence intervals.*
FDA Label Image

Figure3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

Figure3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)
A pharmacokinetic chart titled 'The effects of aripiprazole on pharmacokinetics of other drugs,' showing fold changes and 90% confidence intervals for various drugs metabolized by enzymes including CYP2D6, CYP2C9, 2C19, UGT1A4, and others. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0, and the y-axis lists the affected drugs and pharmacokinetic parameters such as AUC and Cmax.*
FDA Label Image

Figure4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

Figure4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)
A chart titled 'Aripiprazole Fold Change and 90% CI' showing comparative changes in pharmacokinetic parameters (AUC, Cmax) across special population subgroups including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis represents change relative to reference values, ranging from 0.5 to 3.0, with data points and 90% confidence intervals plotted for each subgroup.*
FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)
A horizontal forest plot illustrating the effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics, showing fold changes and 90% confidence intervals in AUC and Cmax. Factors include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment compared to reference groups, with change relative to reference on the x-axis.*
FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)
A Kaplan-Meier curve estimating the cumulative proportion of patients with relapse over 182 days from randomization in a schizophrenia study. The graph compares relapse rates between Aripiprazole and placebo groups, showing days on the x-axis and proportion with relapse on the y-axis, with a table of number of subjects at risk below the x-axis.*
FDA Label Image

71205-480-30 (Aripiprazole Fig7)

71205-480-30 (Aripiprazole Fig7)
Label for Aripiprazole 2 mg tablets by Proficient Rx LP, NDC 71205-480. The label indicates a 30-count bottle of green, modified rectangular, uncoated tablets debossed with '61' on one side and 'H' on the other. Manufactured by Aurobindo Pharma Limited, Hyderabad, India. Includes storage instructions and relabeling information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.